Taiwanese Journal of Obstetrics & Gynecology 54 (2015) 527–531

Contents lists available at ScienceDirect

Taiwanese Journal of Obstetrics & Gynecology

journal homepage: www.tjog-online.com

Original Article

Maternal mosaicism of sex chromosome causes discordant sex chromosomal aneuploidies associated with noninvasive prenatal testing

Leilei Wang [a, 1], Qian Meng [a, 1], Xinxin Tang [a], Ting Yin [a], Jinglu Zhang [a], Shuting Yang [a], Xuyun Wang [a], Haiqian Wu [a], Qingxi Shi [a], Edmund C. Jenkins [b], Nanbert Zhong [a, b], Ying Gu [a, *]

[a] Department of Prenatal Diagnosis, Lianyungang Maternal and Child Health Hospital, Lianyungang, Jiangsu 222001, China
[b] Department of Human Genetics, New York State Institute for Basic Research in Developmental Disabilities, Staten Island, NY 10314, USA

ARTICLE INFO

Article history:
Accepted 29 October 2014

Keywords:
chromosomal aneuploidies
confined placental mosaicism
maternal mosaicism
noninvasive prenatal test
prenatal diagnosis

ABSTRACT

Objective: To investigate the clinical efficiency of noninvasive prenatal test (NIPT) identifying fetal chromosomal aneuploidies.
Materials and methods: In the present study, 917 women with high-risk pregnancies were invited to participate in an NIPT trial based on an Illumina HiSeq massively parallel sequencing platform. Abnormal cases in NIPT were validated by karyotyping and fluorescence *in situ* hybridization (FISH) analysis. All of the participants' infants were examined clinically and followed up for at least 6 months.
Results: A total of 35 (3.82%) high-risk pregnancies were detected with abnormal results in NIPT, which included 25 cases (2.73%) of trisomy 21 (Tri21), four cases (0.44%) of trisomy 18 (Tri18), four cases (0.44%) of Turner syndrome (45, X), one cases (0.11%) of Klinefelter's syndrome (47, XXY), and one cases (0.11%) with lower X chromosome concentration. Further validation indicated that one case of Tri18 and the case with lower X chromosome concentration were false positive results (0.22%) in NIPT. Furthermore, it was found that the false positive case with lower X chromosome concentration in NIPT was caused by maternal sex chromosomal mosaicism (45, X and 46, XX).
Conclusion: Our findings indicated that maternal mosaicism of sex chromosome could cause discordant sex chromosomal aneuploidies associated with NIPT. We highly recommended that maternal karyotype should be confirmed for the cases with abnormal results in NIPT.

Introduction

Chromosome aneuploidies, mostly characterized by trisomy 21 (Tri21), trisomy 18 (Tri18), trisomy 13 (Tri13), and monosomy X [1], lead to medical conditions among neonates requiring specialized medical care and result in emotional and financial challenges to families [2]. The aneuploidies usually occur in one out of every 160 live births and account for 6–11% of all stillbirths and newborn deaths [3,4]. Moreover, the risk of giving birth to a child with chromosomal abnormalities, especially Down syndrome, increases with maternal age [5]. Early diagnosis during the course of pregnancy may inform the family about the potential for a fetus with chromosomal aneuploidy. Therefore, early prenatal screening and diagnosis to detect the most common trisomy are indispensable.

Chromosome aneuploidies are traditionally verified through invasive diagnostic procedures including amniocentesis and umbilical cord blood or chorionic villus sampling [5,6]. These invasive diagnostic procedures require skilled techniques and carry an approximately 0.5–1% risk of miscarriage [5]. In addition, the procedures for conventional prenatal diagnosis take lengthy waiting periods (usually about 14 days). With a culture failure rate of ~1%, many pregnant women dread the sampling and waiting periods

* Corresponding author. Department of Prenatal Diagnosis, Lianyungang Maternal and Child Health Hospital, 10 Cangwu Road, Lianyungang, Jiangsu 222001, China.
E-mail address: yinggulyg@hotmail.com (Y. Gu).
[1] These authors contributed equally.

http://dx.doi.org/10.1016/j.tjog.2014.10.009

[7,8]. Earlier, fetal cell free DNA (cfDNA) was detected in maternal circulating blood [9], which led to the development of noninvasive prenatal test (NIPT) based on analyzing fetal cfDNA in the mother's blood. NIPT is a new platform for prenatal screening and diagnosis of trisomy syndromes with high accuracy and low risk [10–12].

Recently, the use of fetal cfDNA had been reported for the prenatal diagnosis of achondroplasia and myotonic dystrophy, determination of fetal sex, and genotyping of fetal rhesus D [13–16]. However, several problems had restricted the clinical use of the analysis of fetal cfDNA, such as the low concentration of fetal cfDNA in the maternal circulation and the difficulty in distinguishing fetal from maternal chromosomes [17,18]. Moreover, a significant number of false positive results from NIPTs had underlain the biological reasons, including confined placental mosaicism (CPM), maternal mosaicism, co-twin demise, and maternal malignancy [19]. Therefore, more information about NIPT, as well as improvements in its effectiveness, should be made available to pregnant women.

Since 2012, NIPT have been offered as an additional option in our hospital for high-risk pregnant women needing to confirm chromosome aneuploidies. Up until now, 917 high-risk pregnant women from our hospital have participated in an NIPT trial and two discordant results were found. These findings will provide useful information about NIPTs for further improvements.

Patients and methods

Patients

From our prenatal clinics, pregnant women with gestational ages between 14 weeks and 26 weeks meeting any one of the following conditions were considered as high-risk pregnancies: (1) abnormal maternal screening of AFP and free beta-human chorionic gonadotropin; (2) advanced maternal age ($\geq$ 35 years); (3) abnormal ultrasound findings; (4) abnormal amniotic fluid volume; (5) adverse pregnancy history obtained from medical records; and (6) single umbilical artery. Within a 2-year period (January 2012 to December 2013), a total of 917 high-risk pregnancies were identified, and all of them agreed to participate in the NIPT trial. After childbirth, their infants were examined clinically and followed up for at least 6 months. This project was approved by the Hospital Ethics Committee and informed consent was obtained from each participant.

NIPT

Approximately 10 mL blood from each high-risk pregnant woman was collected into a purple-top tube containing EDTA. The blood sample was immediately centrifuged at 1600*g* for 10 minutes at 4°C. The plasma portion was centrifuged at 16,000*g* for 10 minutes to minimize any additional release of maternal DNA. The plasma specimens were frozen on dry ice and sent to a commercial lab that specialized in NIPT (www.berrygenomics.com). The NIPT procedures, including DNA extraction, library construction, whole-genome sequencing, and data analysis, were carried out according to protocols published elsewhere [10]. In brief, plasma DNA was extracted from 1 mL of the plasma using the QIAamp Circulating Nucleic Acid kit from Qiagen (Hilden, Germany). Then, the resulting plasma DNA was used as the input DNA to make a library for sequencing. Plasma DNA libraries were indexed using 6 bp indexing oligos, quantitated by Kapa SYBR fast qPCR kit from Kapa Biosystems (Woburn, MA, USA), pooled, and loaded into one lane in a v2 Illumina HiSeq2000 flow cell (Illumina, USA). Clustering and sequencing were conducted according to Illumina's instruction, using the single-ended 43 bp sequencing protocol. Finally, the sequences were binned for each sample according to the index and mapped to the unmasked human genome sequence (hg19) using the software SOAP2 (obtained from soap.genomics.org.cn/), and the z-score for each chromosome was calculated to judge abnormality referencing to the normalized chromosome representation.

Karyotyping and fluorescence in situ hybridization

For each abnormal woman in NIPT, approximately 20 mL of amniotic fluid and 10 mL of maternal peripheral blood were collected. Conventional karyotyping analysis and fluorescence *in situ* hybridization (FISH) were performed for further validation. Karyotyping was processed using a conventional Giemsa banding (G-binding) method [20], and FISH was performed according to the method previously established [21].

Results

NIPT

A total of 917 high-risk pregnant women were recruited for the NIPT trial. Their ages ranged from 18 years to 46 years with the following distribution: 18–25 years (299, 22.86%), 26–35 years (318, 40.00%), and 36–46 years (300, 37.14%). Among them, the number of women with advanced maternal age, abnormal maternal serum screening, abnormal ultrasonic graphic findings, and other conditions (with abnormal amniotic fluid volume, adverse pregnancy history, or single umbilical artery) were 300 (32.72%), 521 (56.82%), 6 (0.65%), and 90 (9.81%), respectively (Table 1). After NIPT, 34 (3.71%) high-risk pregnancies were found with fetal aneuploidies, which included 25 cases (2.73%) of Tri21, four cases (0.44%) of Tri18, four cases (0.44%) of Turner syndrome (45, X), and one case (0.11%) of Klinefelter's syndrome (47, XXY) (Table 1). Furthermore, one woman (0.11%) was found with lower X chromosome concentration than expected. This finding could have been due to fetal Turner syndrome, but this was considered to be

Table 1
Noninvasive prenatal test (NIPT) result of the high-risk pregnancies.

Groups	Number						
	Participating patients (%)	Abnormal patients in NIPT (%)	Abnormality discovered by NIPT				
			Tri21 (%)	Tri18 (%)	Turner syndrome (45, X) (%)	Klinefelter's syndrome (47,XXY) (%)	Lower X chromosome concentration (%)
Abnormal maternal serum screening	521 (56.82)	10 (1.09)	5 (0.55)	1 (0.11)	3 (0.33)	0 (0)	1 (0.11)
Advanced maternal age	300 (32.72)	13 (1.42)	9 (0.98)	2 (0.22)	1 (0.11)	1 (0.11)	0 (0)
Abnormal ultrasonic finding	6 (0.65)	1 (0.11)	1 (0.11)	0 (0)	0 (0)	0 (0)	0 (0)
Abnormal amniotic fluid volume, adverse pregnancy history, or single umbilical artery	90 (9.81)	11 (1.20)	10 (1.09)	1 (0.11)	0 (0)	0 (0)	0 (0)
Total	917 (100)	35 (3.82)	25 (2.73)	4 (0.44)	4 (0.44)	1 (0.11)	1 (0.11)